Cardialen raises $2.5 million in an equity round for its low-energy atrial fibrillation treatment.
Cardialen is closing in on a $4 million equity round, after raising $2.5 million from 18 unnamed investors.
Minneapolis and St. Louis-based Cardialen is developing a low-energy implant for atrial fibrillation designed to control the fibrillation without damaging heart tissue, according to its website.
The technology uses series of lower-energy pulses rather than a single high-energy shock to effect the therapy, according to the website.
